These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27467592)

  • 1. Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2016; 11(7):e0159904. PubMed ID: 27467592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2014; 9(9):e108511. PubMed ID: 25268703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
    Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
    Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.
    Hill R; Rabb M; Madureira PA; Clements D; Gujar SA; Waisman DM; Giacomantonio CA; Lee PW
    Cell Death Dis; 2013 Sep; 4(9):e791. PubMed ID: 24008735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
    Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
    BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
    Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
    Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
    Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
    da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
    Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
    Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
    Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
    Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
    PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
    Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    MAbs; 2015; 7(1):255-64. PubMed ID: 25587678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.